- Gilteritinib combined with intensive chemotherapy was well-tolerated in newly diagnosed AML patients -

- Accelerating the Discovery and Development of Novel Drugs that Target Mitochondrial Functions -

- A breadth of abstracts highlighting the acute myeloid leukemia treatment landscape, healthcare resource use and cost of care to be presented during oral and poster sessions -

- Grand Prize winner Hernâni Oliveira of Porto, Portugal will receive a $50,000 grant from Astellas plus a one-year nights and weekends membership to MATTER, a healthcare innovation community -

ADC Combination Study Focuses on First-Line Treatment